 There are several updates about CART-E's that are already approved worldwide, being presented here at Ash. Specifically updates from studies looking at bringing CART-E sales further forward in the treatment pathway. Not only studies looking at using CART-E for patients with relapsed refractory myeloma, but also for patients with earlier lines of therapy. For example, Karma II, which is looking at patients who relapse early after their initial line of therapy. Ac mae'n gweithio ddaeth hynny yn ei wneud o'r ddweud o'r cyhoedlmau cael ei carti ar-ferthoedd yn y parwyddiol ar y maelio. A oedd yn mynd i siŵr ei wneud yn ei ffordd yn y gweithio ar-diol, a o'r drafod y cynhyrchu bod y sylwyddiad yn ni'n gweithio sy'n tynnu'n gofynu'r cyflwynt a'r cyflwynt ymlaen i gyflwynt o'r carti. I'r ddweud o'r ddweud i'r ddaeth am fyddwch ymlaen i'n ddweudio'r cyflwynt o'r ddweud o'r cyflwynt. yn cwneud cyfrifentol yw Llaid Gweithgol Lai Llyrstopau? Gweithio i ddod yn teimlo gyda llyfrgyngor Lai Llyrstopau a Llyrstopau yn cyfrifentol yw Llaid Gweithgol. Ac rydym maen nhw'n buffu'r data dwi'n ddigwydd yw dweud cyfrifentol fel設onol yw cyfrifentol gyda eu cyfrifentol a gyrslu llyfrgyngor folkol ar y cyfrifentol llyfrgyngor yma yn trefyd yn llyfrgyngor, ac mae'n gallu ymdyn nhyn nhw'n drwy'r llyfrgyngor Disgusting with patients about the risk of infections after CAR-T and maybe thinking about how we could improve on that going forwards, whether there's anything that we could do to intervene to improve that status for patients to try and help build up those blood count levels to help patients fight infection. So, Allogeneic CAR-T is when we take T-cells not from the patient themselves but from somebody else. So when we're generally talking about CAR-Ts so far, we're talking about taking T-cells from the patient and engineering those T-cells to recognise the myeloma cell and then giving back the T-cells to the patient. But that obviously, that process takes a while, so the T-cells need to be engineered and grown in the laboratory before they can be given back to the patient. Allogeneic CAR-Ts are when we take T-cells from another donor, a different person, and generate CAR-Ts in that way. And the benefit is that you don't then need that long time period to try and grow the patient's own T-cells. They can be off the shelf, they can be readily available at the time when the patient might need treatment. And so, yeah, we're starting to see some of the data coming through from the Allogeneic CAR-T trials. They've started a little bit after some of the other CAR-T trials, so it's still relatively early data in comparison. But it looks very promising and obviously has this advantage of not having to wait for the manufacturing process for patients. So I think access to CAR-T treatments is very different in different countries around Europe. So some of the challenges are around the cost of this treatment. So the manufacturing process takes quite a long time and quite a lot is quite costly to do that for each individual patient. And also CAR-Ts need to be delivered in specialist centres that have experience of harvesting the cells from patients and also delivering the CAR-Ts back to patients and helping to manage some of the side effects that can occur after the CAR-T cells have been delivered. So I think those are the two things for me, really, the cost implications and trying to address that side of things and then building up experience in different centres to try and enable the delivery of CAR-T cells back to patients slightly closer to their home or in the right country for them. So I think both CAR-T and other immunotherapeutic approaches are already starting to change their myeloma treatment landscape. In clinical trials we're seeing lots of data coming through about both of these different immunotherapeutic approaches and incorporating them at different lines of therapy and in different combinations with other treatments. And so I think we're starting to see that change already and so yes, I think over the coming years we'll start to see that even more.